Literature DB >> 17020395

A review of the health-related quality of life and economic impact of Parkinson's disease.

Clare H Dowding1, Claire L Shenton, Sam S Salek.   

Abstract

Parkinson's disease (PD) is a chronic, neurodegenerative disease that places a substantial burden on patients, their families and carers, as well as on society as a whole. PD can severely affect the health-related quality of life (HR-QOL) of both patients and their carers and, as the disease progresses, HR-QOL deteriorates. This review aims to critically evaluate the literature on a number of important aspects that influence HR-QOL in relation to PD. Factors associated with a negative impact and ways to improve HR-QOL are highlighted, and tools for HR-QOL assessment reviewed. The economic impact of PD and related cost-effectiveness studies are also reviewed. Over the course of the disease, patients with PD experience changes in their HR-QOL that are affected by factors such as depression, motor complications, education and surgery. However, a lack of uniformity in the choice of HR-QOL tools used in studies makes comparison of results difficult. Research on motor fluctuations and dyskinesias has shown conflicting results, whereas it is clear from the available data that depression needs to be more clearly recognised and treated. Inequality in the numbers of men and women receiving surgery still needs to be addressed and, again, in this area there is a lack of uniformity with respect to assessment for surgery. Education programmes have been shown to be successful in improving HR-QOL, although more research is needed about how to introduce such programmes to all PD patients. In particular, there has been little detailed research into young-onset PD and juvenile patients to assess the true impact of the disease on their HR-QOL. The literature has also shown that PD can affect the HR-QOL of the carer, which may have a 'knock-on' effect for the patient. The HR-QOL of carers needs more attention because these individuals can significantly reduce the burden that would otherwise fall on the health services in terms of cost and care. Research shows that the economic costs of PD are high, particularly for patients in advanced stages of the disease and those with motor complications. Although carer burden is a major source of costs, this is not factored into cost-effectiveness analyses. Furthermore, because too few studies use quality-adjusted life years as their health outcome, particularly in studies of the costs of surgery, comparison of costs of treatments is difficult. The review highlights the need for HR-QOL tools such as the EuroQol-5D to be used together with disease-specific tools to provide the most comprehensive picture of the costs and impact of PD.A recent upsurge in published literature on PD resulting from increased interest in HR-QOL issues has led to an at times overwhelming amount of new information. The present review assembles the most important points relating to HR-QOL in PD raised in the literature, adds value to previously covered issues, and examines areas of HR-QOL in PD that have not previously been reviewed, such as education, carer burden and surgery, highlighting where more research is warranted.

Entities:  

Mesh:

Year:  2006        PMID: 17020395     DOI: 10.2165/00002512-200623090-00001

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  115 in total

1.  Insomnia and depressive symptoms in patients with Parkinson's disease. Relationship to health-related quality of life. An interview study of patients living at home.

Authors:  M Caap-Ahlgren; O Dehlin
Journal:  Arch Gerontol Geriatr       Date:  2001-02       Impact factor: 3.250

2.  Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs.

Authors:  P David Charles; Bimal B Padaliya; William J Newman; Chandler E Gill; Cassondra D Covington; John Y Fang; Stephanie A So; Michael G Tramontana; Peter E Konrad; Thomas L Davis
Journal:  Parkinsonism Relat Disord       Date:  2004-12       Impact factor: 4.891

3.  Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.

Authors:  M Péchevis; C E Clarke; P Vieregge; B Khoshnood; C Deschaseaux-Voinet; G Berdeaux; M Ziegler
Journal:  Eur J Neurol       Date:  2005-12       Impact factor: 6.089

4.  Validating a quality of life rating scale for idiopathic parkinsonism: Parkinson's Impact Scale (PIMS).

Authors:  S Calne; M Schulzer; E Mak; C Guyette; G Rohs; S Hatchard; D Murphy; J Hodder; C Gagnon; S Weatherby; L Beaudet; J Duff; S Pegler
Journal:  Parkinsonism Relat Disord       Date:  1996-04       Impact factor: 4.891

5.  Stress and family functioning among caregivers of persons with Parkinson's disease.

Authors:  C McRae; P Sherry; K Roper
Journal:  Parkinsonism Relat Disord       Date:  1999-04       Impact factor: 4.891

6.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

7.  Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life.

Authors:  A M Damiano; M M McGrath; M K Willian; C F Snyder; P A LeWitt; P F Reyes; R R Richter; E D Means
Journal:  Qual Life Res       Date:  2000-02       Impact factor: 4.147

8.  Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality.

Authors:  A Schrag; Y Ben-Shlomo; R Brown; C D Marsden; N Quinn
Journal:  Mov Disord       Date:  1998-11       Impact factor: 10.338

9.  A randomized study of the efficacy of the PROPATH Program for patients with Parkinson disease.

Authors:  B S Mercer
Journal:  Arch Neurol       Date:  1996-09

10.  Long-term effects of bilateral subthalamic nucleus stimulation on health-related quality of life in advanced Parkinson's disease.

Authors:  Andrew Siderowf; Jurg L Jaggi; Sharon X Xie; Catherine Loveland-Jones; Lewis Leng; Howard Hurtig; Amy Colcher; Matthew Stern; Kelvin L Chou; Grace Liang; Heather Maccarone; Tanya Simuni; Gordon Baltuch
Journal:  Mov Disord       Date:  2006-06       Impact factor: 10.338

View more
  49 in total

1.  The impact of motor and non motor symptoms on health state values in newly diagnosed idiopathic Parkinson's disease.

Authors:  James Shearer; Colin Green; Carl E Counsell; John P Zajicek
Journal:  J Neurol       Date:  2011-08-05       Impact factor: 4.849

Review 2.  Cost effectiveness of pharmacotherapies in early Parkinson's disease.

Authors:  Karla M Eggert; Jens P Reese; Wolfgang H Oertel; Richard Dodel
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

3.  Health state values during the first year of drug treatment in early-stage Parkinson's disease: a prospective, population-based, cohort study.

Authors:  Corinna Vossius; Odd Bjarte Nilsen; Jan Petter Larsen
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

4.  Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.

Authors:  Gang Chen; Miguel A Garcia-Gordillo; Daniel Collado-Mateo; Borja Del Pozo-Cruz; José C Adsuar; José Manuel Cordero-Ferrera; José María Abellán-Perpiñán; Fernando Ignacio Sánchez-Martínez
Journal:  Patient       Date:  2018-12       Impact factor: 3.883

5.  Impact of community pharmaceutical care on patient health and quality of drug treatment in Parkinson's disease.

Authors:  Sabrina Schröder; Peter Martus; Per Odin; Marion Schaefer
Journal:  Int J Clin Pharm       Date:  2012-07-19

6.  Patient and caregiver perceptions of the social impact of advanced Parkinson's disease and dyskinesias.

Authors:  Alexander Khlebtovsky; Amihai Rigbi; Eldad Melamed; Ilan Ziv; Israel Steiner; Alona Gad; Ruth Djaldetti
Journal:  J Neural Transm (Vienna)       Date:  2012-03-22       Impact factor: 3.575

7.  The role of dispositional mindfulness in a stress-health pathway among Parkinson's disease patients and caregiving partners.

Authors:  Allison Hicks; Kala Phillips; Chelsea Siwik; Paul Salmon; Irene Litvan; Megan E Jablonski; J Vincent Filoteo; Karen Kayser; Sandra E Sephton
Journal:  Qual Life Res       Date:  2019-06-14       Impact factor: 4.147

Review 8.  The prevalence and incidence of Parkinson's disease in China: a systematic review and meta-analysis.

Authors:  Chun-lin Ma; Li Su; Juan-juan Xie; Jian-xiong Long; Peng Wu; Lian Gu
Journal:  J Neural Transm (Vienna)       Date:  2013-09-22       Impact factor: 3.575

9.  Health-related quality of life in Parkinson disease: correlation between Health Utilities Index III and Unified Parkinson's Disease Rating Scale (UPDRS) in U.S. male veterans.

Authors:  Galit Kleiner-Fisman; Matthew B Stern; David N Fisman
Journal:  Health Qual Life Outcomes       Date:  2010-08-30       Impact factor: 3.186

10.  Successful use of rasagiline in combination with two antidepressants: a case report.

Authors:  Narpinder Kaur; Rohit Madan; Ashish Sharma
Journal:  Innov Clin Neurosci       Date:  2012-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.